Pulmonary Pharmacology

Correct Answer

B — Dexamethasone

Rationale

Dexamethasone is classified as a glucocorticoid with no mineralocorticoid activity, making it the preferred corticosteroid for acute respiratory distress syndrome because fluid retention and electrolyte disturbance from mineralocorticoid effects are avoided. The DEXA-ARDS trial established dexamethasone as the agent with demonstrated mortality benefit in moderate-to-severe acute respiratory distress syndrome. Methylprednisolone and hydrocortisone have some mineralocorticoid activity and are used in other critical care contexts such as vasopressor-dependent shock, but they are not the agents with the specific acute respiratory distress syndrome evidence base from DEXA-ARDS. Prednisone is an oral prodrug not used in the acute intensive care unit setting.

Correct Answer

D — Propofol

Rationale

Propofol is classified as a lipid-soluble phenol that potentiates gamma-aminobutyric acid type A receptor activity, producing rapid sedation with an onset of 30 to 60 seconds. It is formulated in a lipid emulsion because its extreme lipophilicity requires a lipid vehicle for intravenous delivery. This lipid emulsion provides significant caloric load and can contribute to hypertriglyceridemia with prolonged use. Midazolam is a benzodiazepine that also potentiates gamma-aminobutyric acid type A receptors but through the benzodiazepine binding site rather than the propofol binding site, and is water-soluble. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist. Fentanyl is an opioid analgesic acting at mu opioid receptors.

Correct Answer

A — Dexmedetomidine

Rationale

Dexmedetomidine is classified as a selective alpha-2 adrenergic receptor agonist. Its sedative mechanism is activation of alpha-2 receptors in the locus coeruleus — the brain's noradrenergic center — which produces a sedation state resembling natural non-rapid eye movement sleep. This mechanism is distinct from all other sedatives used in the intensive care unit. Propofol and midazolam both act through gamma-aminobutyric acid type A receptor potentiation. Ketamine is an N-methyl-D-aspartate receptor antagonist that produces dissociative anesthesia rather than cooperative sedation. The locus coeruleus mechanism explains dexmedetomidine's unique clinical property of producing easily arousable, cooperative sedation without respiratory drive suppression.

Correct Answer

C — Cisatracurium

Rationale

Cisatracurium is classified as an intermediate-duration nondepolarizing neuromuscular blocking agent that undergoes Hofmann elimination — spontaneous, non-enzymatic degradation that occurs at physiological temperature and pH without requiring hepatic or renal function. This organ-independent clearance mechanism makes cisatracurium uniquely suitable for patients with multiorgan dysfunction, where hepatic or renal failure would prolong the duration of action of other agents dependent on these organs for metabolism and elimination. Rocuronium and vecuronium are nondepolarizing agents cleared primarily by hepatic metabolism and biliary excretion. Succinylcholine is a depolarizing neuromuscular blocking agent, not a nondepolarizing one, and is not used for prolonged intensive care unit paralysis.

Correct Answer

B — Sugammadex

Rationale

Sugammadex is classified as a modified gamma-cyclodextrin — a ring-shaped molecule with a hydrophobic cavity that encapsulates rocuronium (and vecuronium) molecules in a 1:1 complex. This encapsulation effectively removes rocuronium from the neuromuscular junction and from plasma, rapidly reversing neuromuscular blockade within minutes regardless of the depth of block. Neostigmine is an acetylcholinesterase inhibitor that reverses nondepolarizing blockade by increasing acetylcholine at the neuromuscular junction, but works only in the presence of spontaneous recovery and requires glycopyrrolate to prevent cholinergic adverse effects. Sugammadex has replaced neostigmine for rocuronium and vecuronium reversal because it works at any depth of block and has no cholinergic adverse effects. Physostigmine is a centrally-acting acetylcholinesterase inhibitor used for anticholinergic toxidrome, not neuromuscular reversal.

Correct Answer

A — Caffeine

Rationale

Caffeine is classified as a methylxanthine and is the drug of choice for apnea of prematurity in neonates. Like theophylline, caffeine antagonizes adenosine receptors — primarily A1 receptors in the respiratory center — increasing respiratory drive and reducing apneic episodes. Caffeine is preferred over theophylline in this setting because it has a substantially wider therapeutic window, requires less frequent monitoring, and has a more favorable adverse effect profile in neonates. The CAP trial demonstrated that caffeine therapy for apnea of prematurity not only reduces apnea but also accelerates successful extubation and reduces rates of bronchopulmonary dysplasia and patent ductus arteriosus. Aminophylline is the intravenous form of theophylline. Roflumilast is a selective phosphodiesterase-4 inhibitor used in chronic obstructive pulmonary disease, not apnea of prematurity.

Correct Answer

D — Mild: 201 to 300 mmHg; moderate: 101 to 200 mmHg; severe: 100 mmHg or below — all measured with at least 5 cmH2O of positive end-expiratory pressure

Rationale

The Berlin definition stratifies acute respiratory distress syndrome severity by the PaO2/FiO2 ratio, measured with at least 5 cmH2O of positive end-expiratory pressure applied. Mild acute respiratory distress syndrome is defined by a ratio of 201 to 300 mmHg; moderate by 101 to 200 mmHg; and severe by 100 mmHg or below. The positive end-expiratory pressure requirement is part of the definition because it standardizes the measurement context — ratios measured without positive end-expiratory pressure may artificially appear better than they are. Severity stratification guides escalation of pharmacological interventions including neuromuscular blockade for severe disease and informs the indication for adjunctive dexamethasone in the moderate-to-severe range. The onset criterion requires respiratory failure within one week of a known clinical insult.

Correct Answer

B — Tidal volume 6 mL/kg predicted body weight; plateau pressure below 30 cmH2O; approximately 22% mortality reduction

Rationale

The ARDSNet trial established that tidal volume limitation to 6 milliliters per kilogram of predicted body weight — not actual body weight — with plateau pressures kept below 30 cmH2O reduces mortality by approximately 22% compared with traditional tidal volumes of 12 milliliters per kilogram. The rationale is that the heterogeneous acute respiratory distress syndrome lung has regions that are flooded and collapsed alongside regions that remain aerated; tidal volumes sized for the full lung weight preferentially overdistend these aerated regions through volutrauma, while repetitive opening and closing of recruitable regions produces atelectrauma. Limiting tidal volume to 6 milliliters per kilogram of predicted body weight distributes ventilation more safely across the available lung. Predicted body weight is used because lung size correlates with height, not actual weight.

Correct Answer

C — Dexamethasone 20 mg intravenously daily for 5 days then 10 mg daily for 5 days; late corticosteroid administration after 14 days has not shown consistent benefit and may be harmful

Rationale

The DEXA-ARDS trial used dexamethasone 20 mg intravenously daily for 5 days followed by 10 mg intravenously daily for 5 days — a step-down protocol totaling 10 days of therapy. This regimen reduced ventilator-free days and 60-day mortality in patients with moderate-to-severe acute respiratory distress syndrome. The timing of corticosteroid administration in acute respiratory distress syndrome is pharmacologically consequential: early administration targets the cytokine-driven inflammatory phase of diffuse alveolar damage, which is glucocorticoid-sensitive. Late corticosteroid administration — after 14 days — coincides with the fibroproliferative phase rather than the inflammatory phase, and has not demonstrated consistent benefit; some evidence suggests potential harm. Dexamethasone is preferred over other glucocorticoids for its favorable potency, duration, and absence of mineralocorticoid activity.

Correct Answer

A — Occurs with prolonged high-dose infusions above 5 mg/kg/hour for more than 48 hours; features include metabolic acidosis, rhabdomyolysis, acute kidney injury, and cardiac arrhythmias; mechanism is impairment of mitochondrial electron transport

Rationale

Propofol infusion syndrome is a rare but potentially fatal syndrome occurring with prolonged high-dose propofol infusions, typically defined as rates above 5 mg/kg/hour for more than 48 hours. The clinical features reflect multiorgan dysfunction: metabolic acidosis, rhabdomyolysis, acute kidney injury, cardiac arrhythmias, and in severe cases lipemic plasma from the lipid emulsion vehicle. The underlying mechanism is impairment of mitochondrial electron transport — propofol at high concentrations disrupts the electron transport chain, impairing cellular energy production and producing lactic acidosis. Monitoring triglyceride levels, lactate, and creatine kinase is recommended in patients receiving prolonged propofol infusions. The syndrome can occur in patients without pre-existing mitochondrial disease and is not related to serotonin pathways.

Correct Answer

D — Dexmedetomidine activates alpha-2 receptors in the locus coeruleus, producing a sedation state resembling natural non-rapid eye movement sleep through a mechanism that does not suppress brainstem respiratory drive

Rationale

Dexmedetomidine's cooperative sedation and preserved respiratory drive both arise from its mechanism of action: selective alpha-2 adrenergic receptor activation in the locus coeruleus. The locus coeruleus is the brain's primary noradrenergic nucleus and regulates arousal and sleep-wake transitions. Inhibiting noradrenergic output from the locus coeruleus produces a sedation state resembling natural non-rapid eye movement sleep, which is a physiological state that preserves respiratory drive because the brainstem respiratory centers are not suppressed by this mechanism. Propofol and benzodiazepines act on gamma-aminobutyric acid type A receptors in a non-physiological manner that produces dose-dependent respiratory depression. The clinical consequence is that patients sedated with dexmedetomidine remain easily arousable, can follow commands, and can participate in weaning assessments — properties that facilitate extubation readiness.

Correct Answer

B — Cisatracurium undergoes Hofmann elimination — spontaneous non-enzymatic degradation at physiological temperature and pH — independent of hepatic or renal function, making its duration of action predictable regardless of organ failure

Rationale

Hofmann elimination is the process by which cisatracurium undergoes spontaneous, non-enzymatic chemical degradation at physiological temperature and pH — the drug breaks down on its own without requiring any enzymatic activity from the liver or kidneys. This organ-independent clearance mechanism makes cisatracurium uniquely suitable for the intensive care unit setting, where patients with acute respiratory distress syndrome often have concurrent multiorgan dysfunction including acute kidney injury and hepatic impairment. Other nondepolarizing agents such as rocuronium and vecuronium depend on hepatic metabolism and biliary or renal excretion; their duration of action is prolonged and unpredictable in multiorgan failure, increasing the risk of intensive care unit-acquired weakness from prolonged neuromuscular blockade. Cisatracurium's predictable elimination is entirely distinct from plasma cholinesterase-dependent hydrolysis, which is the mechanism for succinylcholine and mivacurium.

Correct Answer

C — Inhaled nitric oxide reaches only ventilated alveolar units, producing localized pulmonary vasodilation; it is rapidly inactivated by hemoglobin in pulmonary capillary blood, preventing systemic escape

Rationale

Inhaled nitric oxide achieves selective pulmonary vasodilation through two complementary mechanisms. First, delivery by inhalation means the gas reaches only ventilated alveolar units — flooded or collapsed alveoli receive no drug. This selective delivery produces vasodilation only in areas of ventilated lung, redirecting perfusion toward ventilated units and improving ventilation-perfusion matching and oxygenation. Second, nitric oxide is rapidly inactivated by hemoglobin in the pulmonary capillary blood — it binds to the iron in hemoglobin to form methemoglobin, effectively removing it from circulation before it can reach the systemic arterial bed. This rapid inactivation prevents systemic vasodilation and hypotension. The combination of delivery only to ventilated lung and rapid inactivation at the capillary level confines the vasodilatory effect to the pulmonary circulation.

Correct Answer

A — Corticosteroids reduce laryngeal mucosal inflammation and edema that developed during prolonged endotracheal intubation, decreasing subglottic swelling that would otherwise obstruct airflow after extubation

Rationale

Prolonged endotracheal intubation causes mechanical irritation and pressure injury to the laryngeal mucosa, producing submucosal edema and inflammation in the subglottic space. When the endotracheal tube is removed, this edema reduces the effective diameter of the upper airway, potentially causing turbulent airflow and stridor — or in severe cases, complete obstruction requiring reintubation. A cuff leak test — deflating the endotracheal tube cuff to assess whether air bypasses the tube, indicating adequate subglottic space — identifies patients at high risk. Administering intravenous methylprednisolone or dexamethasone in the hours before planned extubation reduces laryngeal mucosal inflammation and edema through glucocorticoid anti-inflammatory mechanisms, decreasing subglottic swelling and reducing the incidence of post-extubation stridor and reintubation. This is one of the few pre-extubation pharmacological interventions with demonstrated clinical benefit.

Correct Answer

C — Moderate acute respiratory distress syndrome; dexamethasone at 20 mg intravenously daily for 5 days then 10 mg daily for 5 days is indicated based on DEXA-ARDS trial evidence in moderate-to-severe disease

Rationale

A PaO2/FiO2 ratio of 145 mmHg measured with at least 5 cmH2O of positive end-expiratory pressure places this patient in the moderate acute respiratory distress syndrome category by Berlin definition (101 to 200 mmHg). Bilateral infiltrates with appropriate clinical context and the exclusion of cardiac failure fulfill the remaining Berlin criteria. The DEXA-ARDS trial demonstrated that the dexamethasone step-down protocol — 20 mg intravenously daily for 5 days then 10 mg daily for 5 days — reduced ventilator-free days and 60-day mortality in patients with moderate-to-severe acute respiratory distress syndrome, defined in that trial as a PaO2/FiO2 ratio below 200 mmHg. This patient meets that threshold. Early dexamethasone targets the cytokine-driven inflammatory phase of diffuse alveolar damage; late administration after 14 days has not shown benefit and may be harmful. There is no rationale for withholding dexamethasone until day seven.

Correct Answer

B — High-dose prolonged propofol infusion impairs mitochondrial electron transport, producing lactic acidosis, rhabdomyolysis, and acute kidney injury — consistent with propofol infusion syndrome

Rationale

The clinical picture — metabolic acidosis with elevated lactate, rising creatine kinase, and dark urine (myoglobinuria from rhabdomyolysis) in a patient receiving propofol at 6 mg/kg/hour for 60 hours — is consistent with propofol infusion syndrome. The mechanism is impairment of mitochondrial electron transport by propofol at high concentrations, which disrupts cellular energy production and leads to lactic acidosis across multiple organ systems. Skeletal muscle is particularly vulnerable, producing rhabdomyolysis and releasing myoglobin that precipitates in renal tubules to cause acute kidney injury. Cardiac arrhythmias can also occur. The risk conditions — doses above 5 mg/kg/hour and duration beyond 48 hours — are both present in this patient. Propofol infusion syndrome is treated by immediate discontinuation of propofol and switching to an alternative sedative.

Correct Answer

D — Dexmedetomidine produces cooperative sedation through locus coeruleus alpha-2 receptor activation resembling natural sleep, allowing patients to follow commands and tolerate weaning while maintaining respiratory drive that midazolam suppresses

Rationale

Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid type A receptors, producing sedation and amnesia but also respiratory depression and a sedation state where patients cannot meaningfully participate in weaning assessments. Accumulated midazolam from prolonged infusion further prolongs sedation when the rate is reduced. Dexmedetomidine, by contrast, produces cooperative sedation through alpha-2 receptor activation in the locus coeruleus — a mechanism resembling natural non-rapid eye movement sleep that allows patients to be calm at rest but easily aroused, follow commands, and participate in breathing trials. Of equal pharmacological consequence, dexmedetomidine does not suppress respiratory drive, making it uniquely suitable for facilitating extubation readiness. The MIDEX trial demonstrated non-inferiority of dexmedetomidine to midazolam for sedation maintenance, with shorter time to extubation in the dexmedetomidine arm.

Correct Answer

A — Caffeine antagonizes adenosine receptors — primarily A1 receptors in the brainstem respiratory center — increasing respiratory drive and reducing apneic episodes; the CAP trial also demonstrated reduced rates of bronchopulmonary dysplasia and patent ductus arteriosus, and accelerated successful extubation

Rationale

Caffeine, like all methylxanthines, acts as an adenosine receptor antagonist. In the brainstem respiratory center, adenosine acting at A1 receptors inhibits respiratory neuronal activity — a physiological mechanism that in premature neonates with immature respiratory control contributes to central apnea. Caffeine blocks these A1 receptors, removing the inhibitory adenosine tone and increasing respiratory drive, thereby reducing the frequency and severity of apneic episodes. The CAP trial extended beyond demonstrating apnea reduction to show that caffeine therapy accelerated successful extubation from mechanical ventilation and reduced rates of bronchopulmonary dysplasia and patent ductus arteriosus — outcomes with meaningful long-term significance for premature neonates. Caffeine is strongly preferred over theophylline for apnea of prematurity because of its wider therapeutic window, longer half-life enabling once-daily dosing, and more favorable safety profile in neonates.